When is ZJYL's latest earnings report released?
The most recent financial report for Jin medical international ltd. (ZJYL) covers the period of 2024Q4 and was published on 2024/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ZJYL's short-term business performance and financial health. For the latest updates on ZJYL's earnings releases, visit this page regularly.
Where does ZJYL fall in the P/E River chart?
According to historical valuation range analysis, Jin medical international ltd. (ZJYL)'s current price-to-earnings (P/E) ratio is 37.9, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
What is the operating profit of ZJYL?
According to the latest financial report, Jin medical international ltd. (ZJYL) reported an Operating Profit of 1.2M with an Operating Margin of 18.61% this period, representing a growth of 9.94% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is ZJYL's revenue growth?
In the latest financial report, Jin medical international ltd. (ZJYL) announced revenue of 6.47M, with a Year-Over-Year growth rate of -32.35%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much debt does ZJYL have?
As of the end of the reporting period, Jin medical international ltd. (ZJYL) had total debt of 15.92M, with a debt ratio of 0.25. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does ZJYL have?
At the end of the period, Jin medical international ltd. (ZJYL) held Total Cash and Cash Equivalents of 11.13M, accounting for 0.23 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does ZJYL go with three margins increasing?
In the latest report, Jin medical international ltd. (ZJYL) achieved the “three margins increasing” benchmark, with a gross margin of 44.9%%, operating margin of 18.61%%, and net margin of 14.54%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess ZJYL's profit trajectory and future growth potential.
Is ZJYL's EPS continuing to grow?
According to the past four quarterly reports, Jin medical international ltd. (ZJYL)'s earnings per share (EPS) shows a declining trend, with the latest EPS at 0.01. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of ZJYL?
Jin medical international ltd. (ZJYL)'s Free Cash Flow (FCF) for the period is -659.29K, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 353.58% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
